From the House Ear Institute to Hearing and Brain Health

Scientific Publication Spotlight

Dr. Keith Darrow’s latest scientific publication places him alongside two distinguished hearing care leaders, and within a research tradition that helped transform what is possible for people with hearing loss.

Great scientific advances rarely belong to one person. They emerge when researchers, physicians and clinicians bring different perspectives to the same problem, and refuse to accept that the current standard is the final answer. That spirit is visible in a recent publication coauthored by Dr. Keith N. Darrow, PhD, CCC-A; Douglas L. Beck, AuD; and William H. Slattery III, MD.

Published May 4, 2026, in the Journal of Otolaryngology-ENT Research, “A Clinical Perspective: Untreated Hearing Loss and Cognitive Decline” examines why hearing loss should be considered not only a communication problem, but also a potentially important part of the broader cognitive health conversation. The paper connects clinical audiology, neuroscience, neurotology and decades of research into how the ear and brain work together.

The names on the paper matter. Dr. Darrow is joined by two professionals with deep roots in the House Ear Institute, an institution whose work helped move cochlear implants, auditory brainstem implants, hearing in noise testing and translational hearing research from bold ideas toward clinical reality. Their collaboration places today’s hearing and brain health discussion in a remarkable scientific lineage.

Three perspectives, one clinical question

Dr. Darrow contributes the perspective of a neuroscientist, clinical audiologist and educator. Trained through the joint Harvard and MIT programme in Speech and Hearing Bioscience and Technology, his work has consistently focused on translating auditory neuroscience into practical hearing, tinnitus and healthy ageing care. His public message is straightforward: hearing is a brain process, and treatment decisions should reflect the real world consequences of reduced auditory input.

Dr. Douglas Beck contributes more than four decades of clinical, academic and professional education experience. He began his career at the House Ear Institute, working in cochlear implant research and intraoperative cranial nerve monitoring. He later became a director of audiology, an editor and a global educator. The American Academy of Audiology recognised him with its 2026 Excellence in Audiology Award for achievement across clinical care, teaching, mentoring, research and professional service.

Dr. William Slattery contributes the medical and surgical perspective of a leading neurotologist. He joined the House Clinic for a neurotology fellowship in 1993 and has spent more than 30 years treating and studying complex conditions including acoustic neuromas, neurofibromatosis type 2, facial nerve paralysis and implantable hearing technology. Today, the House Institute Foundation identifies him as its CEO and board chair, as well as a clinical researcher whose work has improved treatment for patients worldwide.

Together, the three authors represent an unusually complete continuum: brain science, everyday hearing care, medical diagnosis, surgical treatment, research translation and professional education. That breadth gives their clinical perspective significance beyond any single speciality.

The House Ear Institute: a culture of refusing limits

The House Ear Institute, now the House Institute Foundation, was founded in Los Angeles in 1946. Its history is intertwined with some of the most consequential developments in modern hearing care. William F. House, MD, and engineer Jack Urban developed an early cochlear implant system; a House device became the first cochlear implant approved by the US Food and Drug Administration for adults in 1984. The institute also became the first centre in the world to implant a preschool aged child with a single channel cochlear implant.

Its researchers and physicians helped pioneer the auditory brainstem implant for people whose auditory nerves could not support a cochlear implant. The institute’s history also records the development of the Hearing in Noise Test, or HINT, and research demonstrating how temporal cues contribute to speech recognition, work that influenced processing strategies for hearing aids and implants.

The common thread is translational science: investigation that does not stop with a laboratory finding, but moves toward a diagnostic tool, procedure, technology or clinical protocol capable of changing a patient’s life. The House model has long brought scientists, audiologists, surgeons and engineers into close contact. That same multidisciplinary instinct is evident when Darrow, Beck and Slattery address untreated hearing loss and cognitive decline together.

What the new paper argues

The authors describe hearing loss as a potentially modifiable risk factor associated with cognitive decline, particularly among people who are already at higher risk because of age, cardiovascular disease, diabetes, greater hearing loss or other health factors. They argue that meaningful auditory change may begin before a conventional audiogram makes the problem obvious.

The paper highlights cochlear synaptopathy, extended high frequency loss and difficulty understanding speech in noise as examples of deficits that may disrupt auditory cognitive processing even when traditional thresholds appear relatively normal. Tinnitus and speech in noise difficulty may therefore deserve attention as early signs of auditory vulnerability, not simply inconveniences to be dismissed.

The proposed pathways are interconnected. Degraded sound can require the brain to devote more resources to understanding speech. Communication problems can contribute to withdrawal, anxiety, depression and reduced social engagement. Reduced or distorted auditory input may be associated with changes in neural efficiency and brain structure. These mechanisms remain active areas of investigation, but together they explain why hearing care increasingly belongs in discussions about healthy ageing.

Standing on the shoulders of other leaders

The paper sits within a much larger body of work. Johns Hopkins physician scientist Frank R. Lin, MD, PhD, and colleagues helped establish the modern epidemiological connection between hearing loss, cognitive decline, brain atrophy and dementia risk. Their 2011 longitudinal study found that dementia risk increased with the severity of baseline hearing loss, even after accounting for several other factors.

Dr. Lin later led the ACHIEVE randomised clinical trial, which tested whether a comprehensive hearing intervention could slow cognitive decline. Across the full study population, the hearing intervention did not produce a statistically significant difference in three year cognitive change compared with health education. Among participants drawn from an existing cardiovascular health cohort who had higher baseline risk, however, the intervention was associated with an almost 50% reduction in the rate of cognitive decline over three years.

That nuance is essential. It does not prove that hearing aids prevent dementia in every person, and no ethical clinician should promise that they do. It does show why risk profile, early identification and comprehensive treatment deserve serious study. Darrow, Beck and Slattery translate that evolving evidence into a clinical question: are providers looking broadly enough, early enough, to identify people whose auditory difficulties may carry consequences beyond the ear?

Why speech in noise testing matters

One of the publication’s most practical implications is that a basic hearing screening may not tell the whole story. Many patients say, “I can hear, but I cannot understand,” especially in restaurants, meetings, cars or family gatherings. A quiet room pure tone test is valuable, but it does not fully reproduce those demands.

This is an area closely associated with Dr. Beck’s educational work. He has long advocated for speech in noise assessment as a way to measure functional listening difficulty and inform counselling. Large cohort research has reinforced that importance: a study of more than 82,000 UK Biobank participants found that poorer speech in noise performance was associated with a higher risk of incident dementia over follow up.

An association is not a diagnosis, and a difficult speech in noise result does not mean a patient will develop dementia. It does, however, provide clinically useful information that can be missed when testing ends at audibility. Comprehensive evaluation helps the provider understand not only whether tones are heard, but also how effectively the auditory system supports communication in the environments that shape daily life.

Earlier care, without exaggerated promises

The authors advocate prompt diagnosis and treatment, particularly in midlife and for people with additional risk factors. The most responsible version of that message is neither alarmist nor passive. Hearing treatment is not a cure for Alzheimer’s disease, and current evidence cannot guarantee that one intervention will prevent cognitive decline. Yet untreated hearing difficulty is not benign simply because it develops gradually.

Appropriate care can improve access to conversation, reduce listening effort and help people remain engaged with family, work and community. The ACHIEVE intervention produced substantial improvement in communication, even where a cognitive difference was not detected in the full cohort. Those outcomes matter in their own right.

The clinical opportunity is to identify hearing and listening problems sooner, explain the evidence accurately and build an individualised plan. That plan may include verified hearing technology, communication strategies, tinnitus care, assistive devices, medical referral and continuing follow up. When cognitive concerns are present, collaboration with primary care, neurology, psychology or geriatric professionals can make care safer and more complete.

A bridge between a pioneering past and a prevention focused future

The House Ear Institute became renowned by challenging assumptions about what people with profound hearing loss could regain. Early cochlear implant pioneers faced scepticism, technical obstacles and genuine scientific uncertainty. Progress came through careful experimentation, measurement, collaboration and the willingness to turn evidence into care.

The challenge today is different, but the mindset is familiar. The profession is being asked to look beyond the moment when sound becomes inaudible and consider what happens across decades of effortful listening, reduced communication and changing neural input. Dr. Darrow’s work connects the neuroscience of those questions with the decisions made in ordinary hearing care appointments.

Publishing with Dr. Beck and Dr. Slattery does more than place three respected names on one article. It joins complementary careers: a neuroscientist translating hearing and brain health, an audiologist whose work has spanned implants, cognition and clinical education, and a neurotologist leading an institution built on landmark auditory innovation.

That is the larger significance of this paper. It honours the House tradition of bringing science to the patient while extending that tradition toward prevention, earlier intervention and lifelong brain health. The field’s next great advance may not be one device or procedure. It may be a more complete standard of care, one that recognises hearing as a gateway to communication, connection and cognitive wellbeing, and acts before too much is lost.

Sources and further reading

Editorial note: This article summarises published research for general educational purposes. Associations between hearing loss and cognitive decline do not establish that hearing loss causes dementia, and hearing treatment should not be represented as a guaranteed method of preventing or curing dementia. Individual concerns should be evaluated by qualified hearing and medical professionals.